FRNM — Freenome, Inc.

Is FRNM overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of October 3, 2026

Freenome, Inc. (FRNM) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $16.32. The rating moved from Neutral to Overbought on October 2, 2026.

See all overbought Healthcare stocks →

AI analysis

Freenome, Inc. operates a differentiated multiomics liquid biopsy platform with meaningful upside tied to robust prospective clinical readouts, payer coverage, and commercial execution. Near‑term performance and valuation will hinge on trial data, capital availability, and reimbursement outcomes; sector‑wide risk aversion and cooling IPO appetite increase financing and sentiment pressure. Positive prospective results or strategic partnerships could materially improve the outlook, while adverse data, reimbursement hurdles, or further market dislocation would likely compress valuation and increase dilution risk.

Key factors

  • Proprietary multiomics liquid biopsy platform targeting early cancer detection with differentiated machine‑learning signal integration
  • Clinical validation progress and prospective study readouts are primary near‑term value drivers and can materially re-rate the equity if positive
  • Commercialization path is long and dependent on payer reimbursement, screening guidelines adoption, and provider acceptance
  • Capital intensity and cash burn profile; funding and dilution dynamics will drive near‑term valuation
  • Macro and sector backdrop: cooling healthcare/device IPO window and risk‑off flows reduce appetite for growth/capital‑intensive digital health names
  • Partnerships, strategic collaborations or M&A could provide non‑dilutive capital and distribution scale
  • Limited public filings/context available in the provided EDGAR summary increases uncertainty around current financial runway

Risks

  • Clinical performance risk: insufficient sensitivity/specificity or inconsistent prospective results could undermine clinical utility
  • Reimbursement and guideline risk: Medicare/insurer coverage decisions and IRA‑driven pricing/policy pressure could limit commercial uptake
  • Capital/dilution risk: ongoing R&D and commercialization needs may require additional equity financings at dilutive terms
  • Competitive risk: established and emerging liquid‑biopsy and imaging players could capture market share or set lower price points
  • Regulatory and implementation risk: delays in approvals, site activation, or scaling lab operations could slow revenue realization
  • Market sentiment and macro risk: risk‑off flows, volatile public markets, and healthcare IPO cooling may compress multiples and access to capital
  • Execution risk: commercial rollout, lab network scale, and physician/patient adoption may prove slower than modeled

See today's live rating, score and targets

Members see the live hourly rating for FRNM — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.